Arch Neurol. 2009 Dec;66(12):1552-3.

Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization.

Holtzman DM.

Source

Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA. holtzman@neuro.wustl.edu

Comment on

JAMA. 2009 Jul 22;302(4):385-93.

PMID:: 20008662; [PubMed]

Publication Types

Comment

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Supplemental Content

Related citations

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. [Arch Neurol. 2002]
Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Arch Neurol. 2002 Nov; 59(11):1729-34.
Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau. [Neuro Endocrinol Lett. 2005]
Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
Stuerenburg HJ, Ganzer S, Müller-Thomsen T. Neuro Endocrinol Lett. 2005 Dec; 26(6):696-8.
Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. [Arch Neurol. 2003]
Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism.
Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, Iakovidou V, Maddalena A, Lütjohann D, Ghebremedhin E, et al. Arch Neurol. 2003 Jan; 60(1):29-35.
Review Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. [Mech Ageing Dev. 2001]
Review Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.
Vanmechelen E, Vanderstichele H, Hulstaert F, Andreasen N, Minthon L, Winblad B, Davidsson P, Blennow K. Mech Ageing Dev. 2001 Nov; 122(16):2005-11.
Review [Biochemical markers for Alzheimer disease]. [Ugeskr Laeger. 2006]
Review [Biochemical markers for Alzheimer disease].
Czarna JM, Waldemar G, Heegaard NH. Ugeskr Laeger. 2006 Mar 6; 168(10):1010-4.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realizatio...
Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization.
Arch Neurol. 2009 Dec ;66(12):1552-3.

PubMed
Design and creation of new nanomaterials for therapeutic RNAi.
Design and creation of new nanomaterials for therapeutic RNAi.
ACS Chem Biol. 2007 Apr 24 ;2(4):237-41.

PubMed
Phylogenetic analysis of human rhinovirus capsid protein VP1 and 2A protease cod...
Phylogenetic analysis of human rhinovirus capsid protein VP1 and 2A protease coding sequences confirms shared genus-like relationships with human enteroviruses.
J Gen Virol. 2005 Mar ;86(Pt 3):697-706.

PubMed
Acetylation of MyoD directed by PCAF is necessary for the execution of the muscl...
Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program.
Mol Cell. 1999 Nov ;4(5):725-34.

PubMed
Germline mutation of the tumour suppressor PTEN in Proteus syndrome.
Germline mutation of the tumour suppressor PTEN in Proteus syndrome.
J Med Genet. 2002 Dec ;39(12):937-40.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization.

Source

Comment on

Publication Types

Publication Types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Supplemental Content

Related citations

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information